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CHIMERIC GLUTATHIONE S-TRANSEFERASES: PROPERTIES AND 
THERMODYNAMIC STABILITY 
 
RITA M. ROZMARYNOWYCZ 
 
ABSTRACT 
 
The ultimate goal in protein design is the creation of proteins with desired functions. 
We have constructed  a set of engineered glutathione S-transferases (GST) proteins 
(denoted GSHKTs) in which peptide fragments (of varying lengths from 8 to 16 amino 
acids), derived from human high molecular weight kininogen (HK) domain 5, have been 
inserted into a surface GST loop (between GST residues Gly49 and Leu50). Functionally, 
these hybrid proteins cause inhibition of endothelial cell proliferation in contrast to the 
ancestor GST molecule, which does not. Thus, chimeric GSHKTs can potentially be used 
as therapeutic agents. For a chimeric protein to be used as a therapeutic agent, high 
stability and retention of biological activity through purification and storage steps is 
required. However, as the length of the loop increases, the stability of the protein usually 
decreases. Therefore, we have measured the stability of the GSHKT proteins using 
differential scanning calorimetry (DSC). DSC analyses have shown that all of the 
chimeric GSHKT proteins (independently of the size of the inserted peptide) possess 
roughly 8°C lower stability in comparison with the ancestor GST.  According to the loop 
entropy model, loop closure in proteins becomes entropically more costly as the length of 
the loop increases. For short fragments, no direct relationship between the length of the 
inserted peptide and the destabilizing effect has been observed. Inserting the first two 
residues destabilizes more per residue than the insertion of subsequent longer fragments. 
vii 
 
In an effort to stabilize the GSHKT chimeric proteins, the GST backbone of one of the 
most active chimeras (namely, GSHKT13) was further mutated by removing 1, 2, 3 and 8 
amino acids, respectively in the vicinity of the HK insert (at its N-terminal end). These 
mutants denoted GSHKT13Δ1, GSHKT13Δ2, GSHKT13Δ3, and GSHKT13Δ8, were 
subjected to DSC and found to be roughly two degrees more stable than GSHKT13. 
Although, not as stable as the wild-type GST, these proteins demonstrated increased 
thermostability in comparison with the original GSHKT chimeras. Intrabackbone 
insertions of small peptides into easily expressed, well characterized soluble proteins may 
serve as an approach for creation of novel protein therapeutics. 
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CHAPTER I 
INTRODUCTION 
When the FDA approved the first recombinant therapeutic protein, insulin, over 
25 years ago, protein therapeutics did not greatly contribute to medicine. With now more 
than 130 proteins approved by the FDA for clinical use and many more in development, 
protein therapeutics play a significant role in a variety of medical fields (Leader et al, 
2008).  
In the body, proteins have the most vital and diverse role of any macromolecule. 
Proteins catalyze biochemical reactions, form receptors and channels in membranes, 
provide intracellular and extracellular scaffolding support, and transport molecules within 
a cell or from one organ to another (Leader et al, 2008).  
         When taking into account post-translational modifications and alternative splicing 
of genes the number of proteins or peptides that differ functionally is likely to be much 
higher than the current estimate of ~25,000 different open reading frames in the human 
genome. Because varying concentrations of a protein or an abnormality present in that 
protein may result in disease, this poses a tremendous challenge to modern medicine. 
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However, when viewed from protein therapeutics perspective, this at the same time 
provides a tremendous opportunity for protein therapeutics to mitigate disease. 
1.1 Rational design of proteins 
Designing novel protein drugs can be accomplished using one of two methods. 
The irrational design method (trial and error) also called directed evolution, is based upon 
the principle of evolution. Random mutagenesis is utilized to create a molecular library 
which displays a high level of sequence diversity. High-throughput screening then 
identifies those mutations which produce the desired phenotype (for example, increased 
thermostability, enhanced drug resistance, etc.) and those that are selected are used in the 
next round of random mutagenesis. Rounds are repeated several times until the desired 
result is achieved, mimicking the process of natural selection (Quin et al, 2011). 
Sequence and reason for enhanced protein properties can then be established. This 
method utilizes techniques such as random mutagenesis, error prone PCR and DNA 
shuffling and does not require knowledge of protein structure and function. However, this 
method relies heavily on the ability to test the large number of mutants by a high-
throughput assay, which is often an extremely laborious task (Turner, 2009). 
 The second method applies the growing knowledge of protein structure and function 
to make changes that are predicted to elicit desired improvements (Dalby, 2006). The 
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Table 1. Examples of Commercially Available Protein Drugs 
 
rational design method is widely used for the production of proteins with desirable 
biochemical properties. Knowledge of protein three-dimensional structures in  
combination with computer simulations are utilized to acquire the desired industrial 
features; such as: increased activity and/or thermal stability.  Site-directed mutagenesis is 
then employed to make the necessary mutations and after the protein is obtained, the 
properties can be verified. These R&D efforts are mostly driven by those scientists, who 
seek to understand the relationship between the primary and the three-dimensional 
structure in proteins and further understand and establish fundamental principles of  
molecular recognition (Huisman et al, 2003).  
Name Family  Company  Indication Modification Property 
Proleukin  
(aldesleukin) 
IL-2 Chiron Cancer Mutated free 
cysteine 
(C125A) 
Decreased 
aggregation 
Ontak 
 
Diphtheria 
toxin-IL-2  
Seragen Cancer  Fusion Target       
T-cell 
lymphoma 
Humalog 
(Insulin 
lispro) 
Insulin Eli Lilly Diabetes Lys/Pro 
B28/29 
switched 
Monomer not 
Hexamer 
Fast acting 
Arensp 
(darbepoetin-
alfa) 
EPO Amgen Anemia Additional 
(2) 
glycosylation 
sites 
Increased 
serum half-
life (3x) 
PEGasys 
(peg-
interferon-α-
2a) 
IFN-α Roche Hepatitis 
C 
PEGylation Increased 
serum half-
life (50x) 
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Several proteins are currently being developed and tested in clinical trials using the 
rational design method (Lazar et al, 2003; Marshall et al, 2003; Mehta et al, 2003; Pokala 
et al, 2001; Sheffield, 2001; Sundaram et al, 2002) Table 1 highlights a few examples of 
commercially available protein drugs. A comparison of the rational method and directed 
evolution is shown in figure 1.  
 
Figure 1. Rational Design vs. Directed Evolution Rational design starts from a protein 
structure identifying specific amino acids. Mutations are introduced and the mutant is 
produced and tested for specific properties. Directed evolution starts by subjecting genes 
to random mutagenesis. Libraries of mutants or chimeras are created and desired 
properties can be identified by high-throughput screening (Bomscheuer et. al, 2008). 
 
        The process of rational protein design yet remains a very challenging task, often 
resulting in low protein expression yields, incorrect folding, decreased half-life. In order 
for a designed protein to be used as a therapeutic agent, high stability as well as 
throughout long-term storage are required.  Because proteins are flexible and associated 
with specific biochemical environments, therapeutic activity relies on correct folding, 
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thermodynamics and maintenance of the three-dimensional structure (Greenberg et al, 
2004).  However, protein structures can be easily compromised by pH, temperature, and 
surface interactions. 
 Although many proteins have been developed successfully as therapeutics with 
examples listed in the table above, there are numerous examples of difficulties 
encountered during the development process. Granulocyte colony-stimulating factor (G-
CSF) stimulates the production of white blood cells and is used as a treatment to 
accelerate recovery from neutropaenia in patients after chemotherapy treatment (Vanz, et 
al, 2008). However, it cannot be expressed in its soluble form in Escherichia coli and 
therefore needs to be refolded from inclusion bodies; thus the manufacturing process 
requires additional steps for control of protein activity (Vanz, et al, 2008). Erythropoietin 
(EPO), which increases red blood cell (RBC) production, is an approved treatment for 
anaemia and is usually produced in mammalian cell cultures. However, EPO is a 
thermodynamically unstable protein that is prone to aggregation at elevated temperatures 
and has an unstable intermediate species (Arakawa et al, 2001; Banks et al, 2009). In 
addition, the aggregation of EPO is one of the factors implicated in EPO-derived 
immunogenicity that caused pure red cell applasia incidents (Schellekens et al, 2006). 
The problem of protein solubility and stability of EPO has been partially solved by 
introduction of additional glycosylation sites (Table 1). Many other successful studies 
have applied rational design to the improved conformational stability of enzymes, 
through the introduction of disulphide bonds (Shimaoka et al, 2002; Clark et al, 1993), 
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and/or proline residues that in certain cases have been shown to increase protein stability 
(Suzuki, 1999; Choi et al, 2006). Manipulation of the primary structure, incorporation of 
chemical and posttranslational modifications and utilization of fusion partners; have all 
also lead to improvement of protein stability and biological activity (Huisman et al, 2003; 
Marshall et al, 2003; Pokala et al, 2001).  However, most of the successful examples are 
yet often result from the irrational design of protein or trial-and-error (Huisman et al,  
2003; Marshall et al, 2003; Pokala et al, 2001). 
 
 1.2 Short peptides as therapeutic agents 
 
  Short peptides derived from full-length proteins harbor great potential in drug therapy 
and currently are used in the treatment of a variety of diseases, such as AIDS.  These 
peptides can manifest the activity of the whole protein and can mimic or inhibit the 
activity of the parent protein by interefering with the bonding to the target protein/ 
receptor (e.g. Fuzeon – inhibitor of HIV-1 cell entry) (Greenberg et al, 2004;  Miyamoto 
et al, 2012). Short peptides are advantageous because they are relatively easy to produce 
and do not possess non-desired features of the protein they have been derived from. Table 
2 highlights examples of some potential and available peptide therapeutics. However, 
peptide therapeutics also possess certain disadvantages, which may include low stability, 
enhanced propensity to degradation as well as enhanced propensity for aggregation 
(especially at elevated temperatures). 
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      Table 2. Examples of peptides with high potential for therapeutic applications                                                                                                                                                         
Oxytocin a nonapetide that is used for treatment of bleeding after childbirth or post-
partum hemorrhage (PPH) (Dyer et al, 2010) may represent such an example of a peptide 
unstable at elevated temperatures. Although the availability of this drug has greatly 
Derived from Peptide lengths 
(aa) 
Activity 
Leukocyte function 
associated antigen 1 
(LFA-1) 
10-24 Inhibition of T-cell adhesion 
and function 
Intercellular adhesion                                                                           
molecule (ICAM)-1                                                                                                     
adhesion (Tibbetts et al. 
Peptides, 21, 2000) 
10-25 Inhibition of T-cell adhesion 
and function
Fibroblast growth 
factor (FGF) (Kiyota et 
al. J. Med. Chem., 46, 
2003) 
 
6-17 Mitogenic response 
HIV-1 gp-41 (Sia et al. 
PNAS, 99, 2002) 
14-36  
Fuzeon® 
(Trimers, Roche) 
 
Inhibition of HIV-1 cell 
entry 
Kininogen                               
(Zhang et al. FASEB J., 
14, 2000) (Kawasaki et 
al. JBC, 278, 2003) 
                                                  
8-17 Inhibition of endothelial cell 
proliferation 
Initiation factors eIF4G 
and eIF4E-BP (Herbert 
et al. Curr. Biol., 10, 
2000) 
 
11-12 Induction of Apoptosis 
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reduced maternal mortality rates in the developed world, PPH yet remains a leading cause 
of maternal mortality in developing countries with hot climate; where it is not possible to 
have appropriate conditions for peptide storage (Clyburn et al, 2007). Current 
commercial formulations of oxytocin are insufficiently heat-stable to withstand tropical 
conditions (Hawe et al, 2009). In addition, peptide production can be costly with higher 
concentrations necessary for activity, which also increases likelihood of precipitation. 
Peptides are also not always active in the linear form and are especially susceptible to 
protease degradation. In some cases peptides may require circularization and chemical 
cross-linking for activity. Cambridge, MA, based biotechnology company Aileron 
Therapeutics developed a method to stabilize peptides by ‘‘stapling’’ them with 
hydrocarbon bonds into an α helix formation thus protecting them from protease 
degradation (Wolfson, 2009). Efforts to optimize the activity of short peptides include the 
construction of fusions to increase solubility of the peptide. However, this method will 
not always increase solubility and may not impose enough structural constrains on the 
peptide to achieve desired functionality. A novel approach, in which the short, functional 
peptide is inserted into the backbone of another easy soluble and well expressed protein 
may help to overcome the problems above, shown in figure 2.  
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     However, this method may put limitations on the length of the inserted peptide and 
and in case of the large peptides decrease overall stability of the hybrid. Yet, this 
approach may be beneficial, since in many cases, peptides (due to lack of structural 
constraints) may have a 50 to 200-fold lower activity in comparison with the protein from 
which they were derived (Eckert et al, 1999; Kamiyama et al, 2001; Kawasaki et al, 
2003; Kiyota et al, 2003; Root et al, 2001; Tibbetts et al, 2000; Zhang et al, 2000).  In 
addition to the lack of the structural constraints, the molecular basis for the decreased 
activity may be diminished solubility, stability, and/or propensity for aggregation 
(Church et al, 2001; Daly et al, 2003; Fowler et al, 2005; Kiyota et al, 2003; Sia et al, 
2002; Tibbetts et al, 2000; Zhang et al, 2000). Because short peptides are flexible in 
solution they may fail to adopt a functional conformation (Church et al, 2001; Kiyota et 
al, 2003; Sia et al, 2002; Tibbetts et al, 2000). Some of these problems associated with 
the use of short peptides are listed in table 3. 
Figure 2. Intrabackbone insertion of functional peptide 
Schematic, illustrating insertional approach to create novel 
protein therapeutics. 
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Table 3. Problems associated with the of therapeutic peptides (Avanti, 2012) 
 
 Currently, the introduction of chemical and/or structural constraints may be required to 
retain proper peptide folding, thus mimicking functional motifs and biological activities 
of the parental protein (Church et al, 2001; Kiyota et al, 2003; Sia et al, 2002; Tibbetts et 
al, 2000; Zhang et al, 2000).  These constraints will reduce the conformational space and 
increase activity levels (Kiyota et al, 2003; Sia et al, 2002; Tibbetts et al, 2000).  In 
addition, modifications such as cyclization and/or introduction of intramolecular S-S 
brides, in some cases can promote structural organization (Kiyota et al, 2003; Sia et al, 
2002; Tibbetts et al, 2000). Chemical methods employed in the synthesis of large 
Peptide 
Number of 
amino acids 
Degradation pathways 
Leuprolide 10 
Hydrolysis, isomerization, 
oxidation, and aggregation 
Calcitonin 32 
Deamidation, oxidation, and 
aggregation/fibrilation 
Human Brain Natriuretic 
Peptide [hBNP (1–32)] 
32 
Aggregation, deamidation, and 
oxidation 
HumanParathyroid Hormone 
[hPTH (1–34) 
34 
Aggregation, deamidation, and 
oxidation 
Enfuvirtide (Fuzeon) 36 Deamidation and aggregation 
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amounts of modified and HPLC purified peptides are very costly.  Moreover, production 
of recombinant fusion proteins containing these peptides at their N- or C- termini often 
does not allow sufficient structural constraint for enhancement of activity or solubility. 
Intrabackbone insertions of small peptides into easily expressed, well characterized 
soluble proteins may provide an alternative strategy for the production of a fully 
functional therapeutic grade and cost effective short peptide, figure 3. 
                                                                       
Figure 3. Novel approach to protein redesign Intrabackbone insertion of short peptides 
into a carrier protein may be a useful approach to create therapeutic proteins. 
  1.3 Human High Molecular Weight Kininogen 
Produced in the liver, multifunctional high molecular weight kininogen (HK) plays an 
important role in mammalian vascular biology.  High molecular weight kininogen (HK) 
is a 120 kDa single-chain glycoprotein that plays a central role in contact activation and 
is known to be a cofactor in the intrinsic pathway of blood coagulation cascade (Colman 
et al. 1997). It circulates in complexes with either Factor XI or prekallikrein facilitating 
their optimal orientation on a negatively charged surface (Colman et al. 1984). 
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Kallikrein is then generated which converts Factor XII to Factor XIIa, amplifying the 
contact-activated system of blood coagulation (Colman et al, 1984). HK consists of two 
chains, each comprised of multiple domains (Colman et al, 2000).  Figure 4 shows 
domain structures of high and low molecular weight kininogen. HK domain 5 (D5) has 
cell-binding sites and the motif HGK (histidine, glycine, lysine) was characterized as an 
inhibitor of angiogenesis, endothelial cell proliferation, cell adhesion, invasion, and 
metastasis, figure 5 (Kamiyama et al, 2001; Kawasaki et al, 2003; Zhang et al, 2000).  In 
this context, HGK motif-containing peptides could be a potential target for rational 
peptide design; hence an attractive model to study inhibition of cell proliferation, 
angiogenesis, and metastasis.  These studies will pave a new avenue for the development 
of antiangiogenic and/or anticancer drugs.  However, to date, production of large 
amounts of HGK motif-containing peptides expressed as fusion recombinant remains to 
be optimized.  For example, the production of the HK domain 5 in E. coli as a fusion 
construct with calmodulin-binding protein resulted in inclusion bodies (Zhang et al, 
2002).  The end point is a protein that needs re-folding and several steps of purification in 
order to preserve biological activity (Zhang et al, 2002).  In another study, short and 
chemically synthesized HK containing peptides were shown to be less active than the 
full-length protein (Kamiyama et al, 2001; Kawasaki et al, 2003; Zhang et al, 2002).  
However, intrabackbone insertions of the HGK peptides into a set of carrier proteins 
could provide a novel and unique solution to the problem. 
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Figure 4. High and low molecular weight kininogens domain structures. Single-chain 
high molecular weight kininogen (HK) is comprised of 5 domains, the light chain 
consists of domains 1-3, and the heavy chain consists of domains 5 and 6. Domain 4 links 
the heavy and the light chains, containing the nonapeptide bradykinin (RPPGFSPFR). 
Bradykinin is released HK is cleaved by kallikrein generating two-chain high molecular 
weight kininogen (HKa) in which the heavy and light chains are linked by a single 
disulfide bond between Cys 10 of domain 1 and cys596 of domain 6 (Zhang et al. 2000). 
 
 
 
 
 
 
 
  
 
14 
 
 
                
 
Figure 5. Domain 5 of HKa contains endothelial binding and anionic surface binding 
receptors. An HGK motif derived from this domain was shown to inhibit endothelial cell 
proliferation, angiogenesis, and metastasis (Zhang et al.  2000). 
 
1.4 Schistosoma japonicum glutathione S-transferase 
 Glutathione S- transferases (GSTs) are a diverse family of enzymes evolved from 
the thioredoxin fold.  GSTs catalyze nucleophilic attack by reduced glutathione on 
nonpolar compounds that usually contain electrophilic carbon, nitrogen, or sulphur atoms 
(Cameron et al, 1995). They are involved in the biosynthesis of prostaglandins, 
testosertone, and progesterone and degradation of tyrosine. GSTs are also major 
detoxification enzymes. All of them are dimers with identical or similar subunits. 
Expressed easily and purified from E. coli they have been the subject of many redesign 
efforts. Importantly, GSTs are inert in inhibition of cell-proliferation. Most commonly 
used (as affinity tag for protein purification) GST is derived from Schistosoma 
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japonicum, a pathogenic helminth which causes schistosomiasis. A 26 kDa homodimer 
that is comprised of two 218 amino acid long chains, this enzymes catalytic activity 
comprises the S-conjugation between a thiol group from glutathione with the 
electrophilic moiety of xenobiotic and endobiotic toxic compounds (Kaplan et al, 1997). 
The N-terminal domain contains three -helices and a four-stranded, predominantly 
antiparallel -sheet; The C-terminal domain contains five a-helices and a long coil after 
the final helix (a8) (McTigue et al, 1995). GST, shown in figure 6, was selected to act as 
the backbone because the protein is well studied and several crystallographic structures 
are available (Sheehan et al, 2001). Importantly, GST does not inhibit cell proliferation 
(Kawasaki et al, 2003; Zhang et al, 2000) and the procedure for efficient expression and 
purification of GST from E. coli cells are well established (Sheehan et al, 2001).  
 
  Figure 6. GST derived from Schistosoma japonicum (Bentley et al. 2012) 
 
1.5 Research goal  
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The goal of this project was to create and assess (using differential scanning 
calorimetry) the stability of the several GSHKT chimeric proteins, containing inserts of 
HK peptides. 
Using the rational design method, a number of chimeric proteins were developed 
that increased the functionality of short peptides derived from domain 5 of high 
molecular weight kininogen. These short peptides were inserted into a loop of GST, 
because this protein is biologically inert relevant to the targeted process and because it 
possesses the desired properties of high solubility, stability, and ease of purification. The 
hypothesis that shortening the length of the HGK containing peptide will increase overall 
protein stability was also examined. As the length of the inserted HGK containing peptide 
decreases, the overall stability of the protein will increase. To further stabilize one 
chimeric protein; four mutants were designed from the most stable/active GSHKT 
mutant.  Because the HGK containing peptide could no longer be shortened, due to loss 
of functionality, the backbone protein GST was the focus of these additional redesign 
efforts. Four additional chimeric proteins with truncated GST backbone in the vicinity of 
the insert were thus created. Comparative modeling, insertion mutagenesis and 
expression purification techniques were utilized. The stabilities of the mutants were 
measured using differential scanning calorimetry and activity was assessed by the 
proteins ability to inhibit cell proliferation.  
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Comparative modeling 
Comparative modeling using the 3D-PSSM V2.6.0 algorithm and DeepView 
(Swiss-PdbViewer) was employed for the design efforts of GSHKT proteins. Following 
this algorithm, the sequence of interest was “threaded” into the structure of the ancestor 
molecule and scored for “compatibility”. The GST structure (PDB ID 1M99, S. 
japonicum) was used for redesign efforts of GSHKT16 and mutants. For the redesign 
efforts of stabilizing GSHKT13, (PDB ID 1M99, S. japonicum) model was also used. 
 
2.2 Site-directed Mutagenesis  
The source of GST DNA used was the pGEX-6P-1 vector (GE Healthcare, 
Piscatway, NJ). The hybrid GSHKT proteins were produced using insertional 
mutagenesis. GSHKT16 was produced by amplifying the pGEX-6P-1 vector by PCR 
using PfuTurbo DNA polymerase (Agilent Technologies, Inc., Santa Clara, CA) and the 
  
 
18 
 
following primers: 
5’GCGAAACAAAAAGTTTGAATTGGGTAAGCATGGTCATGGCCACGGAAAA
CATAAAAATAAAGGCAAAAAGAATTTGGAGTTTCCCAATCTTCC-3’ (forward) 
and 5’-GGAAGATTGGGAAACTCCAAATTCTTTTTGCCTTTATTT 
TTATGTTTTCCGTGGCCATGACCATGCTTACCCAATTCAAACTTTTTGTTTC
GC-3’(reverse). DpnI was used to digest the parental DNA that contained methyl groups, 
and the fragments were transformed into E. coli XL10-Gold cells (Agilent Technologies, 
Inc., Santa Clara, CA). GSHKT15, GSHKT14, GSHKT13, GSHKT12, GSHKT11, 
GSHKT10, and GSHKT8 chimeras respectively, were produced using the same approach 
and using the following primers (table 4) that truncated portions of the inserted peptide. 
Figure 7 shows the HGK-containing peptide insert for each of the GSHKT chimeras 
placed between Gly49 and Leu50 of GST amino acid sequence. 
 
  
 
 
 
 
 
 
Table 4. Primers used to create GSHKT chimeras 15, 14, 13, 12, 11, 10, and 8 
 
Pr ot ei n 
 
Pr i mer  
 
 
GSHKT15 
  
5’ - TGAATTGGGTAAGCATGGTCATGGCCACGGAAAACATAAAAATAAAGGCAAAAAGATGGAGTTTCCCAATCT- 3’  
5’ - ACTTAACCCATTCGTACCAGTACCGGTGCCTTTTGTATTTTTATTTCCGTTTTTCTACCTCAAAGGGTTAGA- 3’  
   
 
 
GSHKT14 
 
      
5’ - TGAATTGGGTAAGCATGGTCATGGCCACGGAAAACATAAAAATAAAGGCAAATTGGAGTTTCCCAATCT- 3’  
5’ - ACTTAACCCATTCGTACCAGTACCGGTGCCTTTTGTATTTTTATTTCCGTTTAACCTCAAAGGGTTAGA- 3’  
     
 
 
GSHKT13 
 
 
5’ - TGAATTGGGTAAGCATGGTCATGGCCACGGAAAACATAAAAATAAAGGCAGGAGTTTCCCAATCT- 3’  
5’ - ACTTAACCCATTCGTACCAGTACCGGTGCCTTTTGTATTTTTATTTCCGTACCTCAAAGGGTTAGA- 5’                     
 
 
 
GSHKT12 
 
 
5’ - TTGGGTAAGCATGGTCATGGCCACGGAAAACATAAAAATAAAGTGGAGTTTCCCAATCTTCC- 3’  
5’ - AACCCATTCGTACCAGTACCGGTGCCTTTTGTATTTTTATTTCACCTCAAAGGGTTAGAAGG- 3’  
 
 
 
 
GSHKT11 
 
     
5’ - TTGGGTAAGCATGGTCATGGCCACGGAAAACATAAAAATATGGAGTTTCCCAATCTTCC- 3’  
5’ - AACCCATTCGTACCAGTACCGGTGCCTTTTGTATTTTTATACCTCAAAGGGTTAGAAGG- 3’  
 
 
 
GSHKT10 
                                                                                                                
5’ - TTGGGTAAGCATGGTCATGGCCACGGAAAACATAAATGGAGTTTCCCAATCTTCC- 3’  
5’ - AACCCATTCGTACCAGTACCGGTGCCTTTTGTATTTACCTCAAAGGGTTAGAAGG- 3’  
       
 
  
GSHKT8 
 
                                                                        
5’ - TTGGGGGCCACGGAAAACATAAAAATAAAGTGGAGTTTCCCAATCTTCC- 3’  
5’ - AACCCCCGGTGCCTTTTGTATTTTTATTTCCCTCAAAGGGTTAGAAGG- 3’  
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Figure 7. GSHKT Peptide Inserts with corresponding HGK-containing peptide inserted 
between Gly49 and Leu50 of GST. 
 
For stabilization studies, GSHKT13Δ1, GSHKT13Δ2, GSHKT13Δ3, GSHKT13Δ8 were 
created using the above described strategy and the following primers (table 7). The amino 
acid sequence of GST is provided in figure 8 showing, in GST, which amino acids were 
deleted.  
 
Figure 8. GSHKT13Δ Deletions Amino acid sequence of GST containing 13 amino acid 
peptide insert (colored red). Amino acids that were deleted are colored blue and 
underlined and deletions for each mutation are covered with a red X.  
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Table 5. GSHKT13Δ Primers used to for stabilization studies of GSHKT13 
                             
Automated sequencing was used to confirm mutations at the DNA Sequencing 
Core Facility of the Cleveland Clinic. Primers were diluted to 100 pmol/μL in sterile 
water. The reaction mixture (table 6) was prepared with the appropriate amounts of 
template, primers and Pfu DNA polymerase (Promega, Madison, WI). The amplification 
was performed using The Eppendorf Mastercycler® (table 7). 
 
 
Ingredient 
 
Reaction Mixture  
10x Reaction Buffer 5 µL 
Plasmid  2 µL 
Primer #1 1.25 µL 
Primer #2 1.25 µL 
dNTP mix 1 µL 
H2O 39.5 µL 
Total 50 µL 
Then add:  PfuUltra HF 
DNA polymerase 
1 µL 
                                   Table 6. PCR reaction mixture 
Protein Primer 
GSHKT13Δ1 5’- GCTACTCCACTATTTACCTTGTTTTTCAAA-3’   (forward) 
5’- CGATGAAGGTGATAAATGGAACAAAAAGTTT-3’  (reverse) 
 
GSHKT13Δ2 5’- CTACTTCCACTATTTTTGTTTTTCAAACT-3’ (forward) 
3’- ATGAAGGTGATAAAAACAAAAAGTTTGA-3’ (reverse) 
 
GSHKT13Δ3 5’- CTACTTCCACTATTGTTTTTCAAACT -3’ (forward) 
5’- GATGAAGGTGATAACAAAAAGTTTGA -3’ (reverse) 
 
GSHKT13Δ8 5’- CTCGCGCTACTTCCATTGTT TTTCAAAC (forward) 
5’- GAGCGCGATGAAGGTAACAAAAAGTTTG  (reverse) 
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PCR Step Temperature Time Cycle 
Initial Denaturation 95°C 30 sec 1 
Denaturation 95°C 30 sec 18 
Annealing 60°C 1 min 18 
Extension 68°C 5 min 18 
Final Extension 68°C 5 min 1 
Storage      4°C ∞  
       Table 7. Thermocycler Program PCR amplification of GSHKT13Δ mutants 
 
Dpn 1 was used to digest the parent DNA containing methyl groups and then 
transformed into E. coli XL-10 gold cells (Agilent Technologies, Inc., Santa Clara, CA). 
The sequences that were amplified was then transformed into XL1-Blue Supercompetent 
Cells (Agilent Technologies, Inc., Santa Clara, CA) according to the manufacturer’s 
instructions using Luria Broth instead of SOC and plated on Ampicillin resistant agar 
plates overnight. 10 mL LB-amp was inoculated a single present colony and grown 
overnight for DNA purification at 37°C, 250 RPM. Bacterial cultures were then purified 
using Wizard® Plus Minipreps DNA Purification System (Promega, Madison, WI) 
according to the manufacturer’s instructions. Purified DNA was sequenced at the 
Cleveland Clinic Foundation to verify correctness of the mutation. Purified DNA was 
transformed into BL21 GOLD Competent Cells following the manufacturer’s 
instructions. 
                         
2.3 Expression and Purification of GSHKTs and GSHKT13Δs  
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10 mL of LB-amp broth was inoculated using one colony of E. coli containing a 
recombinant pGEX plasmid and incubated with shaking at 37°C for 5-8 hours. The 
culture was then diluted into fresh, 50 mL LB-amp broth, and grown at 37°C with 
shaking for 12-15 hours. The culture was again diluted into fresh, 1 L LB-amp broth, and 
grown at 37°C with shaking until the OD
600 
reached approximately 0.8. To induce protein 
expression, 1 M IPTG was added to a final concentration of 0.6 mM, and the culture was 
incubated for 3 hours at 30°C. The culture was then centrifuged at 4,000 RPM for 10 
minutes at 4°C to pellet the cells. After discarding the supernatant, the pellet was re-
suspended in 20 mL ice-cold PBS (10 mM Na2HPO4 + 1.8 mM KH2P04 + 140 mM NaCl 
+ 2.7 mM KCl) +10 mM DTT buffer pH 9.0, transferred to 30 mL centrifuge tubes, spun 
at 3500 RPM and stored at -80°C if necessary.  The resultant pellet was resuspended in 
10 mL lysis buffer and the solution was then subjected to sonication (30 second bursts), 
with intermediate cooling ice for two minutes between sonications. The sonicate was then 
centrifuged at 16,000 RPM for 30 minutes at 4°C, and the supernatant was used purified 
using the procedure below.  
Glutathione sepharose 4B beads are supplied as a 75% slurry in 20% ethanol. The 
beads were washed three times with ice-cold PBS to remove the ethanol and re-
suspended in PBS to producing a 50% slurry.  2 ml of the 50% glutathione sepharose 4B 
slurry was then added to 10 ml of resulting supernatant. The mixture was incubated with 
gentle agitation at room temperature for 30 minutes and incubated at 4°C for 1 hour. The 
solution, with adsorbed GSHKT protein, was sedimented by centrifugation at 700xg for 
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10 minutes. The supernatant was discarded and the glutathione sepharose 4B pellet was 
washed three times with PBS, containing 1mM DTT. Supernatant was measured at 
OD280 until it reached approximately 0.01. 1 mL of reduced glutathione elution buffer 
(10 mM reduced glutathione, 50 mM Tris-HCl, pH 8.0 containing 10 mM DTT) was 
added to the sedimented beads. The solution was re-suspended by shaking at room 
temperature for 10 minutes to elute the bound protein. The matrix was re-sedimented by 
centrifugation, and the supernatant stored at -80°C. Elution and centrifugation steps were 
repeated three times, resulting in purified GSHKT protein dissolved in glutathione elution 
buffer. Samples were taken at various stages throughout the above procedures, and stored 
at −20°C for SDS-PAGE analyses. 
Buffer exchange/dialysis 
GSHKT13Δs were buffer exchanged using centrifugal filter units with a 10 kDa 
centrifugal units (Amicon, Millipore) in 20 mM Tris-HCl,  pH 7.5, 10 mM NaCl. 
 
2.4 High Performance Liquid Chromatography (HPLC) 
Size Exclusion Chromatography: Partially purified GSHKT and GSHKT13 mutants 
were applied to Superdex 75 column equilibrated with 1X PBS pH 9.0. Fractions were 
collected and stored at -80°C. In the case that affinity and size exclusion chromatography 
didn’t result in a pure protein preparation an additional step including ion exchange 
chromatography was used. 
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 Ion Exchange Chromatography: Isoelectric points, table 8, were computed for the four 
GSHKT13 mutants using Expasy Compute pI/Mw tool. 
 
Protein Theoretical pI/M 
GSHKT13Δ1 7.14/26746.07 
GSHKT13Δ2 7.14/26559.85 
GSHKT13Δ3 6.79/26431.68 
GSHKT13Δ8 7.69/25859.15 
Table 8. Isoelectric Points of GSHKT13Δs Theoretical pI/MW GSHKT13Δs 
 
Partially purified GSHKT13 proteins were buffer exchanged with 20 mM Tris-
HCl, 10 mM NaCl, pH 8.0 and applied to Mono Q column. Samples were eluted with a 
0.02-1 M NaCl gradient in 20 mM Tris-HCl, pH 8.0 buffer. Fractions were collected and 
stored at -80°C. 
 
2.5 Protein concentration determination  
 
Protein concentration was determined using the Bio-Rad protein assay following the 
manufacturer’s instructions (Bio-Rad, Hercules, CA). Absorbance readings were 
recorded at a wavelength of 595 nm using a Shimadzu UV-1650 PC spectrophotometer 
(Shimadzu Corporation, Japan) and values were compared to a curve drawn from a set of 
BSA standards. 
 
2.6  SDS-PAGE  
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To estimate purity and analyze the protein sample, Laemmli sodium dodecyl-
polyacrylamide gel electrophoresis (SDS-PAGE) was used (Laemmli, 1970). The protein 
samples were separated by SDS-PAGE using the Mini Protean II gel electrophoresis 
system (Bio-Rad, Hercules, CA) with a discontinuous buffer system. 12.5% acrylamide 
gels were run at a constant voltage of 120-180 V, until the dye front reached the bottom 
of the gel. Protein bands were visualised by staining in Coomassie Blue for 1 hour and 
washing for at least one hour in Coomassie Blue destain. 
 
2.7 CD Spectroscopy 
The far-UV CD spectra were acquired on an AVIV Model 202 instrument using a 1-
mm path length quartz cell at 25 °C. Protein concentrations were 0.25 mg/ml in standard 
PBS. 
 
2.8 Cell Culture and Endothelial Cell Proliferation Assay 
HUVECs were isolated from human umbilical cords, and proliferation assays were 
performed. For GSHKT13Δ studies, HUVECs were a kind gift from Dapcel, Inc. The 
effects of recombinant GST, GSHKTs, HK (used as a positive control), and the D5-13 
peptide on cell proliferation were determined by including the proteins in the cell cultures 
for 48 h (Bentley et al, 2012). Gelatin-coated 96-well microplates were used to culture 
endothelial cells at a concentration of 3x10
4
 cells/ml in Medium 199 containing 2% fetal 
bovine serum.  Cells were allowed to adhere and spread during a 4 hour incubation time, 
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the medium was replaced with fresh Medium 199 containing 10 µM Zn
2+,
 1% Cosmic 
calf serum (HyClone, Logan UT), and 10 ng/ml basic FGF (used as a positive control) 
with or without test proteins. Using the CellTiter 96® AQueous cell proliferation assay 
(Promega, Madison, WI), percent inhibition of cell proliferation that GST GSHKT 
chimeras, HK, and HK peptides caused was determined. 
 
2.9 Differential Scanning Calorimetry (DSC) 
The VP-DSC MicroCalorimeter was used to carry out calorimetric experiments 
(Microcal Inc. Northampton, MA.). The DSC was standardized using a set of temperature 
standard capillary tubes made of small amounts of pure paraffin hydrocarbons. 
Temperature standards were measured using an upscan from 10°C – 85°C, at a scan rate 
of 60°C/hour. 
Samples were measured at a concentration of 0.5 mg/ml at a scan rate of 90° C/hour 
at a constant pressure of 25 psi to prevent boiling of the sample during measurement. All 
formulations were analyzed using a VP-DSC (Microcal Inc. Northampton, MA).  
Samples and reference standards were loaded into cells using a gas tight Hamilton 2.5 
mL glass syringe. For data analysis ORIGIN DSC data analysis software was used. 
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Chapter III 
RESULTS 
 
 
3.1 Protein Modeling  
 
GST from S. japonicum was used for redesign efforts following four major 
criteria. First, the HGK-motif containing peptide should be accessible to the solvent. 
Second, the insertion should not introduce side-chain steric conflicts with pre-existing 
atoms. Third, hydrogen bonding and hydrophobic interactions should be disrupted as 
minimally as possible. Fourth, the glutathione binding site should be unaffected. Thus, 
we envisioned that peptides containing the HGK motif would be exposed on the surface 
of the protein and hopefully retain biological activity, perhaps even possessing increased 
activity due to the imposed structural constrains. The largest 16-mer HGK containing 
peptide (KHGHGHGKHKNKGKKN, denoted D5-13) was inserted into the backbone of 
GST commencing redesign efforts. One of the challenges in protein redesign is selecting 
an optimal solution from the enormous amount of sequence and structural possibilities  
(Bentley et al, 2012). It has been shown in the past that protein loops can be engineered 
to have function differently without high degrees of change occurring to the fold of the 
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protein (Sibanda, et al, 1993; Thanki, et al, 1997; Regan, 1999; Pokala, et al, 2001; 
Kuhlman et al, 2002). S. japonicum GST contains 12 major turns/loops (Fig. 9A) 
(Cardoso et al, 2003; McTigue et al, 1995), each loop was considered for alteration. 
 
Figure 9. Comparison of GSHKT16 and GST structures. A, Ribbon diagram of three-
dimensional structure of S. japonicum GST (Protein Data Bank code 1M99). Major 
turn/loop regions are numbered. Domain I is blue. Structural model of the GSHKT16 
protein. Inserted residues side chains are shown in yellow. B, superimposed three-
dimensional structures of S. japonicum GST (code 1M99; in cyan) and the human Pi 
class (code 10GS; in yellow) and Mu class (1HNA; in red) enzymes. The most 
flexible/variable region comprising loops 3 and 4 is circled (Bentley et al. 2012). 
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Because any modifications to loop 1 would introduce steric conflicts, it was 
excluded from alteration; it is also close to the glutathione-binding site. Modifications of 
loops 2, 5, and 6 were excluded, as they would disrupt the central four-stranded β-sheet 
fragment in domain 1 (Bentley et al, 2012). Domains 1 and 2 are connected by loop 7, 
which is involved in intersubunit contacts (Cardoso et al, 2003; McTigue et al, 1995). 
This site was excluded from alterations because mutations may affect the packing of the 
two domains. Domain 2 would likely be disrupted if mutations to loop 11 or 12 were 
introduced. Insertions in loops 3, 4, and 8–10 seemed feasible (Bentley et al, 2012). 
Insertions in loop 4 (Leu-48–Pro-56) seemed at first not to be optimal, as a β-turn 
containing residues 50–53 is involved in intersubunit interactions and in forming the 
hydrophobic contact between Phe-52 of one chain and residues 91–94 and 129–133 of 
the other (Bentley et al, 2012). A statistical algorithm (Chou, et al. 1974) predicted the 
D5-13 peptide (KHGHGHGKHKNKGKKN) to have a disposition to form an α-helix. 
It was assumed that this α-helical region could be accommodated within the short α-helix 
formed by residues 38–42 of GST (Bentley et al, 2012). One important factor is that this 
helix exposed to the solvent (Cardoso et al, 2003; Sheehan et al, 2001) and shows the 
highest degree of structural flexibility and conformational variability between GSTs from 
different organisms and between different GST classes (e.g. between the helminth 
enzyme from S. japonicum used in this study (Protein Data Bank code 1M99) and the 
human Pi class (Oakley et al, 1997) and Mu class (Sheehan et al, 2001; Oakley et al, 
1997) enzymes (ProteinData Bank code 10GS and 1HNA, respectively). 
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Thus, loop 4 was chosen because comparative modeling revealed that insertion of 
16 amino acids of an HGK motif-containing peptide at this site would not significantly 
perturb the GST structure (Bentley et al, 2012).  Insertions were made between Gly-49 
and Leu-50, prior to the β-turn (amino acids 50–53) that is involved in hydrophobic 
subunit contacts (Bentley et al, 2012; Cardoso et al, 2003; McTigue et al, 1995). 
 
 
3.2 Expression, Purification and characterization of chimeric GSHKT16 proteins 
 
 
The hybrid GHSKT16 and mutants were produced using the commercially 
available pGEX-6P-1 vector and amplified by PCR using Pfu-Turbo DNA Polymerase. 
Dpn1 was used to digest parental DNA that contained methyl groups and sequences were 
transformed into E.coli XL-10 gold cells (Agilent Technologies, Inc., Santa Clara, CA). 
The mutagenized plasmid was purified and the correctness of the insertion mutagenesis 
was verified by DNA sequencing.  The recombinant proteins were further expressed in E. 
coli (BL21) cells, found to be soluble and purified on a gluthathione –Sepharose column 
to homogeneity. Figure 10A Shows SDS-PAGE analysis of purified GST and GSHKT16.  
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Figure 10. Characterization of chimeric GSHKT16 protein. A, SDS gel of the 
recombinant GST and GSHKT proteins. B, Gel filtration of GST (upper) and GSHKT 
(lower) on Superdex-75. C, far-UV CD spectra of GST (black line) and GSHKT (red 
line) acquired using a 1-mm path length quartz cell at 25 °C. Protein concentrations were 
~0.25 mg/ml in PBS. (Bentley et al, 2012). 
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The size exclusion chromatogram shown in Figure 10B compares GST and 
GSHKT16.  GSHKT16 behaved as the parental GST molecule and eluted at the position 
characteristic of the GST dimer. Furthermore, the far-UV CD spectra of GST and 
GSHKT showed no major difference between the structures of GSHKT16 and GST, as 
shown in figure 10C. This suggested that the protein satisfied the design criteria 
discussed earlier. 
 
 
3.3 GSHKT16 functionality assays done in collaboration with Dr. Keith McCrae 
 
The function of GSHKT16 was measured by its ability to inhibit the proliferation 
of HUVECs. Although not as potent as full-length two-chain HK (Fig. 11A), 
 
 
Figure 11. Inhibition of HUVEC Proliferation. A, Inhibition of HUVEC proliferation 
by two-chain HK (HKa). B, inhibition of HUVEC proliferation by GSHKT shown to be 
50–100-fold more active than the free D5-13 peptide).C, inhibition of HUVEC 
proliferation by the D5-13 peptide. D, inhibition of HUVEC proliferation by GST (No 
inhibition observed) (Bentley et al, 2012). 
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GSHKT16 was 50–100-fold more active than the free D5-13 peptide 
(KHGHGHGKHKNKGKKN) (IC50 for inhibition of proliferation of ~0.6 µM versus 
~30 µM)  and inhibited HUVEC proliferation in a dose-dependent manner (Fig. 11 B and 
C) (Zhang,et al, 2002). While Parental GST showed no inhibition (Fig. 11D). These 
results suggest that D5-13 was indeed exposed on the surface of GST and presented in a 
conformational state with considerably greater anti-endothelial cell activity compared 
with the free peptide in solution (Bentley et al, 2012). This conformational restraint might 
significantly enhance the interactions of D5-13 with an anti-angiogenic binding site 
expressed on proliferating endothelial cells (Bentley et al, 2012; Kawasaki, et al, 2003). 
However, GSHKT16 is in general not very stable and has a tendency to aggregate and 
precipitate at concentrations above 10 mg/mL and in general was not very stable. 
 
3.4. Expression, Purification, and Characterization GSHKT16 Chimeras— 
 
In an effort to increase the stability of the chimeric protein without substantially 
decreasing its activity we decided to produce several chimeras by shortening the size of 
the insert.  GSHKT15, GSHKT14, GSHKT13, GSHKT12, GSHKT11, GSHKT10, and 
GSHKT8 chimeras contained truncated inserts of the D5-13 peptide were produced.  
These proteins were produced following the same procedures as described for the 
GSHKT16 chimera. Recombinant chimeric proteins were expressed in E. coli (figure 12), 
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found to be soluble, and further purified to homogeneity using the same steps described 
for GSHKT16 (Fig. 13A).  
 
                         
Figure 12. SDS Gels of GSHKT Mutants  showing Expression, purification  
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Figure 13. GSHKT Chimeras Chimeric GSHKT15, GSHKT14, GSHKT13, GSHKT12, 
GSHKT11, GSHKT10, and GSHKT8 proteins (Bentley et al, 2012)  
 
All of the above GSHKT chimeras were dimers (data not shown).  
 
3.5 GSHKT Chimeras Functionality Assays collaboration with Dr. Keith McCrae 
Although the chimeric GSHKT16 protein possessed the desired properties, as has 
been mentioned above, it was prone to aggregation upon freezing and thawing or at high 
concentrations (~10–15 mg/ml). We found that GSHKT15, GSHKT14, GSHKT13, 
GSHKT12, GSHKT11, and GSHKT10 chimeras were slightly less prone to aggregation 
 
Figure 14. Inhibition of HUVEC proliferation. A, denaturing gel electrophoresis. B, 
inhibition of HUVEC proliferation. Hka, two-chain HK. (Bentley et al, 2012) 
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at high protein concentrations and were able to inhibit the proliferation of HUVECs in a 
dose-dependent manner, whereas GSHKT8 (similar to GST) revealed no activity (Fig. 
14B).  
The activities of the GSHKT15 and GSHKT14 chimeras were increased in comparison 
with that of GSHKT16 at lower protein concentrations but were comparable with that of 
GSHKT16 at higher protein concentrations. Overall, a progressive decrease was seen in 
the activity levels of GSHKT13, GSHKT12, GSHKT11, and GSHKT10 chimeras, 
especially as lower concentrations (Fig. 14B). 
 
3.6 Thermal Stability of GSHKT mutants compared to GST 
 
 
 
To gain further and direct insights into the stability of the chimeric GSHKT 
proteins, we subjected them to Differential Scanning Calorimetry (DSC). The DSC 
results of GSHKT chimeras in comparison with the ancestor GST protein (Bentley et al, 
2012) showed ~8–10° lower phase transition temperatures for the GSHKT chimeras 
compared with GST, indicating that the chimeric proteins were indeed less stable than 
native GST (Fig. 15) 
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Figure 15. Left, representative DSC profiles of GST and chimeric GSHKT proteins (Cp 
versus temperature) at a scan rate of 1 °C/min (PBS). Table 9. Right, exact values of Tm. 
(Bentley et al, 2012). 
 
 
Interestingly, the stability of all of the chimeras was quite similar independent of 
the length of the inserted peptides, although GSHKT10 and GSHKT8 demonstrated 
slightly greater stability (Bentley et al, 2012). Table 9 contains exact transition midpoint 
values for GST and  GSHKT chimeras. 
 
 
3.7 Protein Modeling of GSHKT13Δ1, GSHKT13Δ2, GSHKT13Δ3, GSHKT13Δ8 
 
In an attempt to produce more stable GSHKT chimeras we have further undertook 
Table 9.   Tm in PBS 
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additional modeling of the most stable and active chimera (GSHKT13). Modeling was 
aimed at producing GSHKT13 chimeras where parts of the GST protein itself would be 
truncated, since HGK containing peptide could not be truncated further due to loss of 
activity. Figure 16 shows amino acid sequences of GHKT13 chimera with highlighted 
regions indicating amino acidsΔ that were removed from loop 1 in our modeling 
attempts. Figure 17 shows predicted three dimensional models of the GSHKT13 
mutants.  
  
  
  
  
Figure 16. Mutation points of GSHT13Δ1, GSHT13Δ2, GSHT13Δ3 and GSHT13Δ8 
GSHKT13Δ3 GSHKT13Δ8 
GSHKT13Δ2 GSHKT13Δ1 
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Figure 17. GSHKT13Δ1, GSHKT13Δ2, GSHKT13Δ3 and GSHKT13Δ8 structure 
predictions 
 
3.8 Protein Expression and Purification of GSHKT13Δ1, GSHKT13Δ2, 
GSHKT13Δ3, GSHKT13Δ8 
 
 
 The same protein expression and purification protocol that was used for isolation 
of GSHKT mutants was further applied for the isolation of GSHKT13Δ1, GSHKT13Δ2, 
GSHKT13Δ1 
GSHKT13Δ3 GSHKT13Δ8 
GSHKT13Δ2 
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GSHKT13Δ3 and GSHKT13Δ8 from E. coli cells. However, we found that during 
affinity purification, all four GSHKT13Δ chimeras began to elute from the Glutathione-
Sepharose 4B beads during the first washing step indicating a much lower affinity for the 
beads.  Figure 18 shows the expression and purification of the four GSHKT13Δs.   
 
Figure 18. GSHKT13Δ mutant expression, purification 
  
 
Purification of GSHKT13Δs by size exclusion chromatography is shown in figure 19 by a 
representative chromatogram.  
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 Manual run 8:10_UV  Manual run 8:10_Logbook  Manual run 8:10_P960_Flow
  0
100
200
300
400
mAU
  0  20  40  60  80 100 ml 
              Figure 19. Size exclusion chromatogram of GSHKT13Δ purification 
 
     The large peak, occurring around 11 minutes, represents the GSHKT13Δ dimer. The 
small peak following represents the monomer of the protein. SDS-PAGE analysis shows 
purified GSHKT13Δs compared to GST and GSHKT13 were ~26 kDa. Overall purity of 
GSHKT13 mutants was ~ 95%. In an effort to further purify the proteins, ion-exchange 
chromatography was employed. Figure 18A shows purification of GSHKT13Δs by ion 
exchange chromatography on Mono Q 5/50  
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 Manual run 3:10_UV  Manual run 3:10_Conc  Manual run 3:10_Logbook  Manual run 3:10_P960_Flow
  0
 20
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Figure 20. A. Ion-exchange chromatogram of GSHKT13Δs and B.SDS-PAGE 
showing >95% purified GSHKT13Δs. 
 
 
GL column. Isoelectric points were determined for each GSHKT13Δs using Expasy 
compute pI/Mw tool.. Figure 20 B shows the SDS-PAGE analysis indicating >98% 
purity of the GSHKT13Δ1, GSHKT13Δ2, GSHKT13Δ3 and GSHKT13Δ8. Mutants are 
also compared with GST and GSHKT13.  After purification, total concentrations were 
measured and protein concentration after two freeze-thaw cycles was also measured. 
Results indicated greater GSHKT13Δ stability to freeze-thaws in comparison with the 
original GSHKT16. 
  
 
3.9 Thermodynamic Stability of GSHKT13Δ1, GSHKT13Δ2, GSHKT13Δ3 and 
GSHKT13Δ8 
B A 
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Table 10. 
 Protein  Tm 
GST 55.845 
GSHKT13 47.257 
GSHKT13Δ1 49.267 
GSHKT13Δ2 49.008 
GSHKT13Δ3 47.762 
GSHKT13Δ8 48.999 
Figure 21. Superimposed DSC profiles of GSHKT13Δs. Table 10. shows exact Tm 
values of GSHKT13Δs. 
 
The stabilities of GSHKT13Δ1, GSHKT13Δ2, GSHKT13Δ3 and GSHKT13Δ8 mutants 
were all assessed by DSC. All four mutants showed roughly similar stability at ~49°C; 
about two degrees more stable than the GSHKT13 protein. 
 
3.10 GSHKT13Δ functionality assay 
 
The function of GSHKT13Δs was measured by its ability to inhibit cell 
proliferation of HUVECs. While GSHKT13 showed activity, all four of the GSHKT13Δs 
GST 
GSHKT13 
GSHKT13Δ1 
GSHKT13Δ2 
GSHKT13Δ3 
GSHKT13Δ8 
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showed no inhibition, suggesting that the D5-13 peptide was no longer exposed on the 
surface of GST.  
 
 
 
 
 
 
Figure 22. Inhibition of HUVEC proliferation. Inhibition of HUVEC proliferation. 
Hka, two-chain HK.  
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Chapter IV 
 
DISCUSSION 
 
  The rational design of novel proteins may provide additional insights into protein 
structure, folding, and function. Since initial attempts, the field of protein design has 
progressed to the point that it is now possible to consider tertiary and quaternary 
structures and even functional elements for construction of new proteins (Bentley et al, 
2012; Pokala et al, 2001; Marshal et al, 2003; Lazar et al, 2003; Ladurner et al, 1997). In 
our recently published study (Bentley et al 2012), where part of this work has been 
described, a novel approach to design chimeric proteins containing inserts of short 
functional peptides with the potential to be used as therapeutic agents has been presented. 
These chimeric proteins harbored functional peptides in a loop region of GST; peptides 
which contain an HGK-rich motif derived from a sequence within domain 5 of high 
molecular weight kininogen (Bentley et al, 2012). These HGK peptides contain 
endothelial cell-binding sites and inhibit angiogenesis by causing apoptosis of 
proliferating endothelial cells and inhibit endothelial cell proliferation and migration 
(Zhang et al, 2000;  Daly et al, 2003; Zhang et al, 2002;  Zhang et al, 2002; Colman, et al, 
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2000; Kamiyama et al, 2000; Kawasaki, et al, 2003). This motif was also found to block 
tumor metastasis (Zhang et al, 2000;  Daly et al, 2003; Zhang et al, 2002;  Zhang et al, 
2002; Colman et al, 2000; Kamiyama et al, 2000; Kawasaki et al, 2003).  
Domain 5 of high molecular weight kininogen as well as the recombinant peptide 
derived from domain 5 induces endothelial cell apoptosis with an IC50 in the low 
nanomolar range; the isolated D5 peptides express at least 2 logs lower activity (Bentley 
et al, 2012). The peptides inability to maintain the appropriate conformation for 
endothelial cell interaction may be the reason for this (Zhang et al, 2000;  Daly et al, 
2003; Zhang et al, 2002;  Zhang et al, 2002; Colman, et al, 2000; Kamiyama et al, 2000; 
Kawasaki et al, 2003). Our functional study done in collaboration with Dr. Keith McCrae 
demonstrates that imposing structural constrains on these flexible peptides may enhance 
activity of the HGK peptide (Bentley et al, 2012) and that this method may be potentially 
be useful for many other biological applications. 
Constraining methods, in the past, have enhanced biological activity to short 
peptides (Tibbetts et al, 2000; Zhang et al, 2000; Church et al, 2001; Sia et al, 2002;  
Kiyota et al, 2003).  Past studies have shown that cyclization or introduction of 
intramolecular S–S bridges may promote structural organization of the short functional 
peptides and enhance their biological activity. For example, cyclization or introduction of 
intramolecular S–S bridges enhanced the activity of short peptides derived from LFA-1 
(leukocyte function-associated antigen 1) and ICAM-1 (intercellular adhesion molecule 
1)
 
(Tibbetts et al, 2000). Introduction of chemical constraints and crosslinks has also been 
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shown to enhance the structural organization and biological activity of short peptides 
derived from FGF and HIV-1 gp41 protein (Sia et al, 2002; Kiyota et al, 2003). We 
proposed an alternative method in which biologically active peptides are inserted into 
loops of biologically inert (relevant to the targeted process) proteins that possess are 
highly soluble, stable, and easily purified (Bentley et al, 2012). This novel approach may 
prove useful in defining the functions of small peptides and potentially provide insight 
into the development of new therapeutic agents (Bentley et al, 2012). 
GST from S. japonicum was chosen because it commonly used for affinity 
purification of fusion proteins expressed in E. coli (Bentley et al, 2012; Thanki et al, 
1997) and several crystallographic structures are available (Cardoso et al, 2003; 
McTigue, et al, 1997; Sheehan et al, 2001). Importantly, GST does not inhibit cell 
proliferation (Zhang et al, 2000; Kawasaki et al, 2003). In the past, production of peptides 
that contain the HGK motif were expressed as fusions with various recombinant proteins. 
This did not enhance their biological activity (Zhang et al, 2000; Zhang et al, 2002; 
Zhang et al, 2002; Kawasaki et al, 2003).  HK D5 was produced in E. coli as a 
calmodulin fusion protein which resulted in inclusion bodies, that required renaturation to 
re-establish biological activity (Zhang et al, 2002).  In our recently published study, the 
GSHKT proteins were shown to be soluble (Bentley et al, 2012); however, we found that 
all of them are thermodynamically less stable than the ancestor GST (Bentley et al, 
2012). Generally, it is accepted that loops can be broken and engineered to have different 
functions without serious consequences to the overall folding of the protein (Sibanda et 
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al, 1993; Thanki et al, 1997; Regan, 1999; Pokala et al, 2001; Kuhlman et al, 2002), 
however increase in loop length generally leads to the decrease in protein stability.  Nagi 
and Regan explored a relatioship between loop length and stability for the four-helix 
bundle RNA-binding protein Rop (Nagi et al, 1997). They have replaced a short loop 
region consisting of two amino acids (Asp30, Ala31) with a range of 1 to 10 glycine 
residues and found that the structure of ROP can accommodate a much longer, more 
flexible loop than occurs in the wild-type protein. They have found that all 10 mutants 
that contain glycine residues fold into native-like structures which can bind RNA. They 
also found that as loop length increases, the stability of the protein toward both thermal 
and chemical denaturation decreases (Nagi et al, 1997). In this study, Nagi and Regan 
chose the amino acid glycine to replace the natural loop of the protein. There are several 
reasons for this. Because glycine is a commonly occurring residue found in loops, it is a 
poor alpha helix former (Nagi et al, 1997) and therefore unlikely to continue the first 
alpha helix through the loop region. Because glycine lacks a side chain, potential 
interactions are minimized and backbone conformational freedom is maximized, within 
the loop and between the loop and the helices.  
These experiments took into account that the polyglycine peptide closely 
approximated that of a random-walk polymer due to glycines symmetry and small side 
chain. The polypeptide inserts of eight GSHKT chimeras don’t contain a string of 
identical residues, like the mutants in this experiment. Rather, the inserted polypeptide 
contains varying residues with larger side chains. (KHGHGHGKHKNKGKKN) is 
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predicted by the Chou and Fasman algorithm to have the propensity to from an alpha-
helix (Chou et al, 1974).
 
 
The influence on stability of the length of an amino-acid sequence inserted into 
loops has been thoroughly studied for small proteins, like that of the 63 amino acid 
protein ROP (Collinet et al, 2001). Yeast phosphoglycerate kinase (PGK) has been 
studied in the past as a folding model representative of large, multidomain proteins 
(Collinet et al, 2001). PGK is a monomeric two domain protein composed of 415 resides. 
A group in France led by Dr. Desmadril inserted short unstructured sequences (four Gly 
or four Thr) into the loops of yPGK to study stability of the mutants (Collinet et al, 
2001). Coinciding with our current findings, they found that, for short insertions, there is 
no direct relationship between the length of the inserted peptide and the destabilizing 
effect of the insertion (Collinet et al, 2001). Interestingly, insertion of two residues was 
found to be more destabilizing per residue than the insertion of longer sequences in such 
way that the protein could accommodate a further extension for the inserted motif with a 
limited energetic penalty (Collinet et al, 2001). They found that all mutated proteins 
could refold efficiently and that the effect per residue on stability is larger for the first 
inserted residue (Collinet et al, 2001). In another study, Ladurner and Fersht studied the 
effects of glycine, alanine and glutamine repeat insertions on the stability and folding of 
chymostrypsin inhibitor-2 (CI2). They inserted peptides of 7 to 13 residues in length into 
loops of the protein and found that stability and folding of the protein was minimally 
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affected. They suggested that unstructured polypeptide chains in protein loops do not 
have a great energetic penalty (Ladurner et al, 1997).  
GSHKT mutants loop insertions differ from these studies because the inserted 
amino acid sequence is varied; not a string of glycines or alanines. The mutants contained 
a natural string of amino acids rather than. GSHKT mutants were overall around 7 
degrees less stable than Schistosoma japonicum GST.  
Because GSHKT13 was one of the two mutants that were successfully crystallized, it was 
chosen for further studies to enhance thermal stabilization and hopefully activity. Four 
mutants were engineered by removing a loop region connecting an alpha helix to a beta 
sheet in GST. Arg42 was removed from GSHKT13Δ1, Arg42, Try41 were removed from 
GSHKT13Δ2; Arg42, Try41, Lys40, were removed from GSHKT13Δ3, and Arg42, 
Try41, Lys40, Asp39, Gly38, Glu37, Asp36, Arg35 were removed from GSHKT13Δ8. 
Comparative modeling revealed that, even after the deletion of 1-8 amino acids 
connecting an alpha helix to a beta sheet, the area of the functional peptide insert was still 
solvent exposed; important so the protein would retain activity. The resulting 
GSHKT13Δs thermal stability was characterized using DSC in which all were found to 
be roughly two degrees more stable than GSHKT13. Though not as stable as the original 
GST, all four mutants show potential for decreased flexibility of the area of the functional 
peptide insert which may imply that they possess retained or even enhanced activity.  
This two degree increase in stability could likely be a result of an increase in non-
covalent interactions that, during heating, ensure more heat is required to unfold the 
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protein. Although the overall stability was increased by the following mutations, 
GSHKT13Δs stability was lower than that of the ancestor Schistosoma japonicum GST 
which is five degrees more stable. By adding glycines of up to 10 residues in length into a 
loop of the four helix bundle protein ROP RNA-binding activity was retained in all 
mutants (Nagi et al. 1997). However, in this case, the increase in stability led to a 
complete loss in functionality.   In the past, it has been demonstrated that an increase in 
protein stability can lead to decrease in activity. Mutating basic residues to alanine in the 
active site of barnase led to an increase in stability by 0.15-0.64 kcal mol
-1
, while 
decreasing activity by 15-99% (Meiering et al, 1992).  A combination of several point 
mutations made in T4 lysozyme led to mutants with higher stabilities but a gradual 
decrease in activity (Zhang et al, 1995). In our case, truncating one to eight amino acids 
in the backbone of GSHKT13Δ mutants led to, essentially, a complete loss in activity 
suggesting that the active HGK-motif containing peptide was no longer accessible to the 
solvent and was unable to bind to a negatively charged region of the cell surface. The 
Chou-Fasman algorithm predicted the HGK-motif containing peptide possessed the 
propensity to form an alpha-helix.  Mutations to the GST backbone in the GSHKT13Δ 
mutants may have changed the positioning of the HGK-motif containing peptide 
orienting it to the core of the protein.   The action by which Hka inhibits cell proliferation 
has yet to be shown, but may follow a similar pathway as the mechanism underlying Hka 
antiangiogenic activity.  In this pathway, Hka acts as an antiadhesive ligand by displacing 
vitronectin. Prekallikrein is converted to kalliekrein at the endothelial surface by an 
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endothelial cell cysteine protease. Hka can augment cell-bound plasmin-dependent 
proteolysis to facilitate endothelial cell migration (Colman et al. 2000). 
 
It has been suggested that loops do not actively dictate the final protein fold 
(Sibanda, et al, 1993; Kuhlman et al, 2002; Nagi et al, 1997; Collinet et al, 2001; 
Ladurner et al, 1997). However, an increase in loop length usually leads to a decrease in 
protein stability (Nagi et al, 1997; Collinet et al, 2001). Our GSHKT10 and GSHKT13 
crystal structures (data not shown) indicate that insertions of 10 and 13 residues increase 
the flexibility of a surface loop significantly, providing an explanation for the observed 
decrease in thermodynamic stability for these chimeras. In contrast, insertions of 7–13-
residue stretches of glycine, alanine, and glutamine repeats had minimal effects on the 
stability and folding of chymotrypsin inhibitor-2 (Ladurner et al, 1997). This suggests 
that local environment is an important factor and that the presence of certain (e.g. 
unstructured) regions in proteins does not necessarily have a great impact on energetic 
penalty (Ladurner et al, 1997). Although a variety of strategies have emerged for rational 
design of proteins, including manipulation of primary structure, incorporation of 
chemical and post-translational modifications, and utilization of fusion partners (Pokala 
et al, 2001; Marshall et al, 2003; Lazar et al, 2003; Sundaram et al, 2002; Mehta et al, 
2003; Sheffield, 2001), successful efforts have often resulted from trial and error 
(Marshall et al, 2003). For biologically active peptides to function therapeutically, they 
must be produced efficiently, be highly soluble, and retention of biological activity are 
required. The stability and solubility (but not the activity) of therapeutic peptides can 
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sometimes be enhanced through fusion to a soluble protein with a long biological half-
life (e.g. albumin fusion with the anticoagulant proteins/peptides hirudin and barbourin) 
(Sundaram et al, 2002).  Intra-backbone insertions of small peptides into easily 
expressed, well characterized soluble proteins may provide a unique and different 
solution to the problem. 
 
4.1 Future Directions 
Now that data have been provided showing the successful design and 
characterization (thermostability and activity) of four chimeric GSHKT13Δ proteins, our 
next step is to attempt crystallization of these proteins for structural analysis.  
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